We are excited to announce that RS BioTherapeutics has successfully secured a significant funding round to further our mission of developing life-changing therapies for individuals suffering from pulmonary inflammation-related diseases. In this latest round, we have raised $10 million, bolstering our efforts to advance our first investigational compound, RSBT-001. This groundbreaking therapeutic is poised to revolutionize the treatment landscape by offering a novel alternative to traditional corticosteroids for chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis, asthma, and even challenges associated with SARS-CoV-2.
RSBT-001 stands out as a first-in-class solution that utilizes the immune-modulating properties of specific anti-inflammatory cannabinoids, delivered through our unique polarity adaptive transport mechanism. This innovative approach allows us to target the inflammatory cascade in the lungs at multiple levels, significantly reducing pulmonary inflammation and restoring respiratory function. With this new funding, we are focused on advancing our preclinical studies and preparing for our Investigational New Drug (IND) application, which we are targeting for early 2025.
This funding achievement underscores the confidence that investors have in our pioneering work at RS BioTherapeutics. We remain committed to improving the lives of millions worldwide who struggle with debilitating respiratory conditions. As we move forward, we'll continue to harness cutting-edge science and medicine to deliver transformative treatments for pulmonary inflammation. Stay tuned for more updates as we embark on this crucial journey.
